Langaware utilizes AI-driven speech and voice analysis to detect and monitor neurodegenerative diseases, including Mild Cognitive Impairment, Alzheimer’s disease, and Depression, through proprietary digital biomarkers. This technology enables early and objective diagnosis, significantly improving treatment outcomes and reducing the time to specialist referral for patients at risk.
Funding
$4.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
EVFounders
Product
Problem
Early detection of neurodegenerative diseases like Alzheimer's and depression relies on subjective assessments and specialist referrals, leading to delays in diagnosis and treatment. Traditional methods often lack the sensitivity to detect subtle cognitive changes in the early stages of disease progression. Undiagnosed or late-stage diagnoses can result in increased healthcare costs and reduced quality of life for patients.
Solution
Langaware offers an AI-powered platform that analyzes speech and voice patterns to detect early signs of cognitive and mental health decline. The platform uses proprietary digital biomarkers extracted from brief audio samples to identify subtle changes indicative of conditions like Mild Cognitive Impairment (MCI), Alzheimer's disease (AD), and depression. By providing objective and rapid results, Langaware enables primary care physicians and other healthcare providers to identify at-risk individuals, expedite referrals to specialists, and initiate timely interventions. The solution aims to improve patient outcomes, reduce healthcare costs, and enhance the accuracy of clinical trials by facilitating early and objective disease detection.
Target Audience
Langaware targets healthcare providers (primary care physicians, specialists), payers, life science companies, and corporate wellness programs seeking to improve early detection and management of cognitive and mental health conditions.
Features
- AI-driven analysis of speech and voice samples using proprietary digital biomarkers
- Detection of Mild Cognitive Impairment (MCI), Alzheimer’s disease (AD), and Depression
- Rapid results delivered within minutes
- High accuracy: 90% Sensitivity and 85% Specificity for Dementia, 83% Sensitivity and 80% Specificity for Depression
- Education-independent and unbiased testing suitable for self-administration, in-person, or remote settings
- Comprehensive report with 7 data points to aid clinical decision-making